ElsaLys takes rights to Transgene's anti-CD115 mAb for immuno-oncology
ElsaLys SAS licensed all development and marketing rights to Transgene SA’s immune-oncology candidate TG3003, which it will rename ELB041.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.